New combo aims to shorten treatment for rare blood cancer
NCT ID NCT07169565
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a three-drug combination (ibrutinib, bendamustine, and rituximab) given for a fixed duration in people with Waldenström macroglobulinemia, a rare blood cancer. The study has two parts: first, finding the safest dose of bendamustine, and then testing that dose in more patients to check safety and early signs of effectiveness. Only 21 participants will be enrolled, and the goal is to see if a time-limited approach can control the disease without requiring lifelong medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ibrutinib, bendamustine, and rituximab
- What this could lead to
- If successful, this could lead to a fixed-duration treatment option for Waldenström macroglobulinemia, potentially reducing the need for lifelong therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 21 participants. The main goal is safety and dose-finding, not proof of effectiveness. Side effects from the drug combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.